Cargando…
A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we have measure...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Milan
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579961/ https://www.ncbi.nlm.nih.gov/pubmed/33087040 http://dx.doi.org/10.1186/s10194-020-01193-4 |